{"protocolSection":{"identificationModule":{"nctId":"NCT04921397","orgStudyIdInfo":{"id":"2021XS-001"},"organization":{"fullName":"Dongzhimen Hospital, Beijing","class":"OTHER"},"briefTitle":"China Stroke Registry for Patients With Traditional Chinese Medicine","officialTitle":"China Stroke Registry for Patients With Traditional Chinese Medicine (CASES-TCM): A Prospective, Multicenter, Observational Study","acronym":"CASES-TCM"},"statusModule":{"statusVerifiedDate":"2021-06","overallStatus":"NOT_YET_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2021-06-11","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2024-12-31","type":"ESTIMATED"},"completionDateStruct":{"date":"2025-06-01","type":"ESTIMATED"},"studyFirstSubmitDate":"2021-06-01","studyFirstSubmitQcDate":"2021-06-07","studyFirstPostDateStruct":{"date":"2021-06-10","type":"ACTUAL"},"lastUpdateSubmitDate":"2021-06-07","lastUpdatePostDateStruct":{"date":"2021-06-10","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Ying Gao","investigatorTitle":"President of Institute for Brain Disorders, Beijing University of Chinese Medicine","investigatorAffiliation":"Dongzhimen Hospital, Beijing"},"leadSponsor":{"name":"Dongzhimen Hospital, Beijing","class":"OTHER"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The CASES-TCM study is a prospective, multicenter, observational study, which will enroll 20,000 patients with acute stroke (ischemic stroke or intracerebral hemorrhage) within 7 days of symptom onset.\n\nThis study attempts to depict major clinical characteristics of acute stroke in patients with Chinese medicine treatment and to explore any difference compared with other non-Chinese medicine use cohorts and the effectiveness and safety of Chinese medicine."},"conditionsModule":{"conditions":["Ischemic Stroke","Intracerebral Hemorrhage"]},"designModule":{"studyType":"OBSERVATIONAL","patientRegistry":true,"targetDuration":"24 Months","designInfo":{"observationalModel":"OTHER","timePerspective":"PROSPECTIVE"},"enrollmentInfo":{"count":20000,"type":"ESTIMATED"}},"outcomesModule":{"primaryOutcomes":[{"measure":"Distribution of scores on the modified Rankin scale at 3-month follow-up","description":"Modified Rankin Scale, a commonly used scale for measuring the degree of dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. 0 - No symptoms.1 -No significant disability. Able to carry out all usual activities, despite some symptoms.2 - Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.3 - Moderate disability. Requires some help, but able to walk unassisted.4 - Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.5 - Severe disability. Requires constant nursing care and attention, bedridden, incontinent.6 - Dead.","timeFrame":"3 months follow-up"},{"measure":"Recurrent stroke events (ischemic stroke, hemorrhagic stroke including intracerebral hemorrhage and subarachnoid hemorrhage) within 12-month follow-up","description":"Number of patients with new ischemic stroke and hemorrhagic stroke within 12 months of follow-up.","timeFrame":"12 months follow-up"}],"secondaryOutcomes":[{"measure":"Proportion of patients receive Chinese medicine treatment within 24 hours after admission","description":"Chinese medicine treatment exposure defined as whether patients receive Chinese medicine injection, oral Chinese patent medicine, or compound Chinese medicine.","timeFrame":"24 hours after admission"},{"measure":"Chinese medicine treatment duration within 3-month, 12-month, and 24-month follow-up","description":"Chinese medicine treatment duration will be assessed using proportion of days covered, which is a percentage of days covered with the medicine in the number of days the patient is eligible to have the medication.","timeFrame":"3 months, 12 months, and 24 months follow-up"},{"measure":"Change in the National Institutes of Health Stroke Scale score between baseline (admission) and discharge","description":"National Institute of Health Stroke Scale is a tool used by healthcare providers to objectively quantify the impairment caused by a stroke. It is composed of 11 items, each of which scores a specific ability between a 0 and 4. For each item, a score of 0 typically indicates normal function in that specific ability, while a higher score is indicative of some level of impairment. The individual scores from each item are summed in order to calculate a patient's total NIHSS score. The maximum possible score is 42, with the minimum score being a 0.","timeFrame":"At admission (baseline) and discharge (14 days - mean for length of hospitalization for stroke patients)"},{"measure":"Patient-Reported Outcomes Scale for Stroke score at discharge","description":"Patient-Reported Outcomes Scale for Stroke, a structured questionnaire-scale was developed suitable for Chinese patients. The score ranges from 0 (best) to 144 (worst).","timeFrame":"At discharge (14 days - mean for length of hospitalization for stroke patients)"},{"measure":"Proportion of patients with modified Rankin Scale score ≤2 at 3-month and 12-month follow-up","description":"Modified Rankin Scale, a commonly used scale for measuring the degree of dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. 0 - No symptoms.1 -No significant disability. Able to carry out all usual activities, despite some symptoms.2 - Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.3 - Moderate disability. Requires some help, but able to walk unassisted.4 - Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.5 - Severe disability. Requires constant nursing care and attention, bedridden, incontinent.6 - Dead.","timeFrame":"3 months, 12 months follow-up"},{"measure":"Distribution of scores on the modified Rankin scale at 12-month follow-up","description":"Modified Rankin Scale, a commonly used scale for measuring the degree of dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. 0 - No symptoms.1 -No significant disability. Able to carry out all usual activities, despite some symptoms.2 - Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.3 - Moderate disability. Requires some help, but able to walk unassisted.4 - Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.5 - Severe disability. Requires constant nursing care and attention, bedridden, incontinent.6 - Dead.","timeFrame":"12 months follow-up"},{"measure":"Proportion of patients with Barthel Index score ≥90 at 3-month and 12-month follow-up","description":"Barthel Index is a commonly used scale for measuring the activity of daily living of people. Score of 10-item scale ranges from 0 (worst) to 100 (best).","timeFrame":"3 months, 12 months follow-up"},{"measure":"Recurrent stroke events (ischemic stroke, hemorrhagic stroke including intracerebral hemorrhage and subarachnoid hemorrhage) within 3-month and 24-month follow-up","description":"Number of patients with new ischemic stroke and hemorrhagic stroke events within 3 months and 24 months of follow-up.","timeFrame":"3 months, 24 months follow-up"},{"measure":"Composite of new clinical vascular events within 3-month, 12-month, and 24-month follow-up","description":"Number of patients with new clinical vascular events (ischemic stroke/ hemorrhagic stroke/ transient ischemic attack / myocardial infarction /vascular death) within 3 months, 12 months, and 24 months of follow-up.","timeFrame":"3 months, 12 months, 24 months follow-up"},{"measure":"Mini-Mental State Examination scale score at 3-month, 12-month, and 24-month follow-up","description":"Mini-Mental State Examination scale is a commonly used scale for measuring the cognitive function. Range: 0 to 30 points, higher points represent a better outcome.","timeFrame":"3 months, 12 months, 24 months follow-up"},{"measure":"All-cause mortality within 12-month and 24-month follow-up","description":"Number of patients who died within 12 months and 24 months of follow-up.","timeFrame":"12 months, 24 months follow-up"},{"measure":"Incidence of adverse events","description":"Number of patients with any adverse events (including serious adverse events) during the study.","timeFrame":"Up to 24 months follow-up"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* ≥18 years of age\n* Diagnosed as acute ischemic stroke or intracerebral hemorrhage\n* Within 7 days of symptom onset\n\nExclusion Criteria:\n\n* Refusal to give informed consent\n* Have difficulties completing follow-up","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"],"studyPopulation":"Patients who meet the criteria will be consecutively enrolled from 100 participating sites in China.","samplingMethod":"NON_PROBABILITY_SAMPLE"},"contactsLocationsModule":{"centralContacts":[{"name":"Ying Gao","role":"CONTACT","phone":"+86-10-84013209","email":"gaoying973@163.com"}],"overallOfficials":[{"name":"Ying Gao","affiliation":"Dongzhimen Hospital, Beijing University of Chinese Medicine","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Dongzhimen Hospital","city":"Beijing","state":"Beijing","zip":"100700","country":"China","contacts":[{"name":"Ying Gao","role":"CONTACT","email":"gaoying973@163.com"}],"geoPoint":{"lat":39.9075,"lon":116.39723}}]},"referencesModule":{"references":[{"pmid":"34531755","type":"DERIVED","citation":"Feng L, Kong L, Dong X, Lai X, Zhang D, Ren B, Liu S, Xie X, Li C, Song Y, Du Y, Cao K, Zhang C, Gao Y; CASES-TCM Protocol Steering Group. China Stroke Registry for Patients With Traditional Chinese Medicine (CASES-TCM): Rationale and Design of a Prospective, Multicenter, Observational Study. Front Pharmacol. 2021 Aug 31;12:743883. doi: 10.3389/fphar.2021.743883. eCollection 2021."}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000002543","term":"Cerebral Hemorrhage"},{"id":"D000006470","term":"Hemorrhage"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000020300","term":"Intracranial Hemorrhages"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M9246","name":"Hemorrhage","asFound":"Hemorrhage","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5482","name":"Cerebral Hemorrhage","asFound":"Intracerebral Hemorrhage","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M21803","name":"Intracranial Hemorrhages","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]}},"hasResults":false}